Clinician compliance with laboratory monitoring and prescribing guidelines in HIV 1-infected patients receiving tenofovir

BACKGROUND: Tenofovir is part of the preferred first-line regimen for HIV-infected patients in South Africa (SA), but is associated with kidney toxicity. SA antiretroviral therapy (ART) guidelines recommend creatinine monitoring at baseline (ART start) and at 3, 6 and 12 months, and substituting tenofovir with zidovudine, stavudine or abacavir should creatinine clearance (CrCl) decrease to <50 mL/min OBJECTIVE: To assess clinician compliance with tenofovir monitoring and prescribing guidelines METHODS: We described the proportion of adult patients on tenofovir-based first-line ART who were screened for baseline renal impairment, were monitored according to the SA antiretroviral treatment guidelines, and were switched from tenofovir if renal function declined RESULTS: We included 13 168 patients who started ART from 2010 to 2012. Creatinine concentrations were recorded in 11 712 (88.9%) patients on tenofovir at baseline, 9 135/11 657 (78.4%) at 3 months, 5 426/10 554 (51.4%) at 6 months, and 5 949/ 8 421 (70.6%) at 12 months. At baseline, 227 (1.9%) started tenofovir despite a CrCl <50 mL/min. While on tenofovir, 525 patients had at least one CrCl of <50 mL/min. Of 382 patients with &gt;3 months' follow-up after a CrCl <50 mL/min, 114 (29.8%) stopped tenofovir within 3 months. Clinicians were more likely to stop tenofovir in patients with lower CrCl and CD4 count. Of 226 patients who continued to receive tenofovir and had further CrCls available, 156 (69.0%) had a CrCl &gt;50 mL/min at their next visit CONLUSIONS: Creatinine monitoring is feasible where access to laboratory services is good. Kidney function recovered in most patients who continued to receive tenofovir despite a CrCl <50 mL/min. Further research is needed to determine how best to monitor renal function with tenofovir in resource-limited settings

Saved in:
Bibliographic Details
Main Authors: de Waal,R, Cohen,K, Fox,M P, Stinson,K, Maartens,G, Boulle,A, Davies,M-A
Format: Digital revista
Language:English
Published: South African Medical Association 2016
Online Access:http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S0256-95742016000400024
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0256-95742016000400024
record_format ojs
spelling oai:scielo:S0256-957420160004000242016-04-20Clinician compliance with laboratory monitoring and prescribing guidelines in HIV 1-infected patients receiving tenofovirde Waal,RCohen,KFox,M PStinson,KMaartens,GBoulle,ADavies,M-ABACKGROUND: Tenofovir is part of the preferred first-line regimen for HIV-infected patients in South Africa (SA), but is associated with kidney toxicity. SA antiretroviral therapy (ART) guidelines recommend creatinine monitoring at baseline (ART start) and at 3, 6 and 12 months, and substituting tenofovir with zidovudine, stavudine or abacavir should creatinine clearance (CrCl) decrease to <50 mL/min OBJECTIVE: To assess clinician compliance with tenofovir monitoring and prescribing guidelines METHODS: We described the proportion of adult patients on tenofovir-based first-line ART who were screened for baseline renal impairment, were monitored according to the SA antiretroviral treatment guidelines, and were switched from tenofovir if renal function declined RESULTS: We included 13 168 patients who started ART from 2010 to 2012. Creatinine concentrations were recorded in 11 712 (88.9%) patients on tenofovir at baseline, 9 135/11 657 (78.4%) at 3 months, 5 426/10 554 (51.4%) at 6 months, and 5 949/ 8 421 (70.6%) at 12 months. At baseline, 227 (1.9%) started tenofovir despite a CrCl <50 mL/min. While on tenofovir, 525 patients had at least one CrCl of <50 mL/min. Of 382 patients with &gt;3 months' follow-up after a CrCl <50 mL/min, 114 (29.8%) stopped tenofovir within 3 months. Clinicians were more likely to stop tenofovir in patients with lower CrCl and CD4 count. Of 226 patients who continued to receive tenofovir and had further CrCls available, 156 (69.0%) had a CrCl &gt;50 mL/min at their next visit CONLUSIONS: Creatinine monitoring is feasible where access to laboratory services is good. Kidney function recovered in most patients who continued to receive tenofovir despite a CrCl <50 mL/min. Further research is needed to determine how best to monitor renal function with tenofovir in resource-limited settingsSouth African Medical AssociationSAMJ: South African Medical Journal v.106 n.4 20162016-04-01journal articletext/htmlhttp://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S0256-95742016000400024en
institution SCIELO
collection OJS
country Sudáfrica
countrycode ZA
component Revista
access En linea
databasecode rev-scielo-za
tag revista
region África del Sur
libraryname SciELO
language English
format Digital
author de Waal,R
Cohen,K
Fox,M P
Stinson,K
Maartens,G
Boulle,A
Davies,M-A
spellingShingle de Waal,R
Cohen,K
Fox,M P
Stinson,K
Maartens,G
Boulle,A
Davies,M-A
Clinician compliance with laboratory monitoring and prescribing guidelines in HIV 1-infected patients receiving tenofovir
author_facet de Waal,R
Cohen,K
Fox,M P
Stinson,K
Maartens,G
Boulle,A
Davies,M-A
author_sort de Waal,R
title Clinician compliance with laboratory monitoring and prescribing guidelines in HIV 1-infected patients receiving tenofovir
title_short Clinician compliance with laboratory monitoring and prescribing guidelines in HIV 1-infected patients receiving tenofovir
title_full Clinician compliance with laboratory monitoring and prescribing guidelines in HIV 1-infected patients receiving tenofovir
title_fullStr Clinician compliance with laboratory monitoring and prescribing guidelines in HIV 1-infected patients receiving tenofovir
title_full_unstemmed Clinician compliance with laboratory monitoring and prescribing guidelines in HIV 1-infected patients receiving tenofovir
title_sort clinician compliance with laboratory monitoring and prescribing guidelines in hiv 1-infected patients receiving tenofovir
description BACKGROUND: Tenofovir is part of the preferred first-line regimen for HIV-infected patients in South Africa (SA), but is associated with kidney toxicity. SA antiretroviral therapy (ART) guidelines recommend creatinine monitoring at baseline (ART start) and at 3, 6 and 12 months, and substituting tenofovir with zidovudine, stavudine or abacavir should creatinine clearance (CrCl) decrease to <50 mL/min OBJECTIVE: To assess clinician compliance with tenofovir monitoring and prescribing guidelines METHODS: We described the proportion of adult patients on tenofovir-based first-line ART who were screened for baseline renal impairment, were monitored according to the SA antiretroviral treatment guidelines, and were switched from tenofovir if renal function declined RESULTS: We included 13 168 patients who started ART from 2010 to 2012. Creatinine concentrations were recorded in 11 712 (88.9%) patients on tenofovir at baseline, 9 135/11 657 (78.4%) at 3 months, 5 426/10 554 (51.4%) at 6 months, and 5 949/ 8 421 (70.6%) at 12 months. At baseline, 227 (1.9%) started tenofovir despite a CrCl <50 mL/min. While on tenofovir, 525 patients had at least one CrCl of <50 mL/min. Of 382 patients with &gt;3 months' follow-up after a CrCl <50 mL/min, 114 (29.8%) stopped tenofovir within 3 months. Clinicians were more likely to stop tenofovir in patients with lower CrCl and CD4 count. Of 226 patients who continued to receive tenofovir and had further CrCls available, 156 (69.0%) had a CrCl &gt;50 mL/min at their next visit CONLUSIONS: Creatinine monitoring is feasible where access to laboratory services is good. Kidney function recovered in most patients who continued to receive tenofovir despite a CrCl <50 mL/min. Further research is needed to determine how best to monitor renal function with tenofovir in resource-limited settings
publisher South African Medical Association
publishDate 2016
url http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S0256-95742016000400024
work_keys_str_mv AT dewaalr cliniciancompliancewithlaboratorymonitoringandprescribingguidelinesinhiv1infectedpatientsreceivingtenofovir
AT cohenk cliniciancompliancewithlaboratorymonitoringandprescribingguidelinesinhiv1infectedpatientsreceivingtenofovir
AT foxmp cliniciancompliancewithlaboratorymonitoringandprescribingguidelinesinhiv1infectedpatientsreceivingtenofovir
AT stinsonk cliniciancompliancewithlaboratorymonitoringandprescribingguidelinesinhiv1infectedpatientsreceivingtenofovir
AT maartensg cliniciancompliancewithlaboratorymonitoringandprescribingguidelinesinhiv1infectedpatientsreceivingtenofovir
AT boullea cliniciancompliancewithlaboratorymonitoringandprescribingguidelinesinhiv1infectedpatientsreceivingtenofovir
AT daviesma cliniciancompliancewithlaboratorymonitoringandprescribingguidelinesinhiv1infectedpatientsreceivingtenofovir
_version_ 1756005786166755328